The high incidence of multidrug-resistant (MDR) bacteria among patients admitted to ICUs has determined an increase of tigecycline (TGC) use for the treatment of severe infections. Many concerns have been raised about the efficacy of this molecule and increased dosages have been proposed. Our purpose is to investigate TGC safety and efficacy at higher than standard doses.
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., Antonelli, M., High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria, <<CRITICAL CARE>>, 2014; 18 (3): R90-R90. [doi:10.1186/cc13858] [http://hdl.handle.net/10807/65015]
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
De Pascale, Gennaro;Montini, Luca;Pennisi, Mariano Alberto;Bernini, Valentina;Maviglia, Riccardo;Bello, Giuseppe;Spanu, Teresa;Tumbarello, Mario;Antonelli, Massimo
2014
Abstract
The high incidence of multidrug-resistant (MDR) bacteria among patients admitted to ICUs has determined an increase of tigecycline (TGC) use for the treatment of severe infections. Many concerns have been raised about the efficacy of this molecule and increased dosages have been proposed. Our purpose is to investigate TGC safety and efficacy at higher than standard doses.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
